Table 1 Clinical characteristics describing the study participants
| Â | Number | Percentage |
|---|---|---|
Patients | 211* | 100 |
Age at first sampling year, mean ± SD | 73.0 ± 8.91 |  |
Tumor stage at diagnosis | ||
 T1/2 | 44 | 20.9 |
 T3/4 | 50 | 23.7 |
 M1 | 74 | 35.1 |
 Node-positive | 15 | 7.1 |
 Not specified | 28 | 13.3 |
Gleason score at diagnosis | ||
 ≤ 7 | 72 | 34.1 |
 8–10 | 108 | 51.2 |
 Not specified | 31 | 14.7 |
Primary treatment | ||
 ADT (± RT/CT) | 125 | 59.2 |
 Radical Px (± RT) | 61 | 28.9 |
 Radical Px + ADT | 7 | 3.3 |
 Other | 18 | 8.5 |
Metastatic burden at first sampling | ||
 LN only | 31 | 14.7 |
 Bone only | 73 | 34.6 |
 Bone and LN | 61 | 28.9 |
 Visceral and bone and/or LN | 34 | 16.1 |
 Not specified | 12 | 5.7 |
Stage at first sampling (all patients, n = 217) | ||
 mHNPC | 23 | 10.6 |
 mHSPC1 | 6 | 2.8 |
 mCRPC | 188 | 86.6 |